Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Motexafin gadolinium - Pharmacyclics

Drug Profile

Motexafin gadolinium - Pharmacyclics

Alternative Names: API-GP3; FP-GP1; Gadolinium (III) texaphyrin; Gadolinium texaphyrin; Gd-Tex; Gd-texaphyrin; GdT2B2; MGd; PCI-0120; Xcytrin

Latest Information Update: 15 May 2014

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pharmacyclics
  • Class Antineoplastics; Lanthanoid series elements; Metallotexaphyrins; Small molecules
  • Mechanism of Action Thioredoxin reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Amyotrophic lateral sclerosis; Brain cancer; Chronic lymphocytic leukaemia; Glioblastoma; Glioma; Head and neck cancer; Lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Renal cancer; Solid tumours

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 01 Mar 2014 Pharmacyclics terminates a phase II trial in Chronic lymphocytic leukaemia and small lymphocytic lymphoma in USA (NCT00100711)
  • 13 Jun 2008 Final efficacy data from a phase I/II trial in non-Hodgkin's lymphoma released by Pharmacyclics
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top